Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Joy Cuthbertson
+44 (0)77614 01203
joycuthbertson@msn.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Therapeutic implications of oral hypoglycaemic agents on the enteroinsular axis in type 2 diabetes
Back

Therapeutic implications of oral hypoglycaemic agents on the enteroinsular axis in type 2 diabetes

Not Recruiting

Open to: All Genders

Age: Adult

Northern Ireland

Medical Conditions

Type 2 diabetes

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Not provided at time of registration

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

03 Aug 2005 01 Aug 2007

Publications

2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19538242 results2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/20152998 results2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21194775 results

Interventional

Intervention Type : Drug
Intervention Description : Drugs/placebo administered in Study A and B:

A/B 1: one placebo tablet (oral) stat dose A/B 2: 1 g metformin (oral) stat dose A/B 3: 120 mg nateglinide (oral) stat dose

In Study A and B all subjects received the two drugs and placebo, one at a time in different orders as single doses, at each visit one week apart. The subjects were given a standard mixed meal. Study B was extended with subjects returning; this time they were kept fasting. In Study A subjects were not on any oral hypoglycaemic agents. In Study B if any of the subjects were on an oral hypoglycaemic agent this was stopped for a 3-week washout period prior to starting the study.

In Study C and D the subjects received all three combinations below, one combination as a single dose at a time, one week apart:

Cross-over combinations for study C: C1: placebo (oral) and 1.5 nmol/kg body weight GLP-1 subcutaneous (sc) stat dose C2: 120 mg nateglinide (oral) and 1.5 nmol/kg body weight GLP-1 sc stat dose C3: 120 mg nateglinide (oral) and 1 ml normal saline sc stat dose

Cross-over combinations for Study D:D1: placebo (oral) and 1.5 nmol/kg body weight GLP-1 sc stat dose D2: 1 g metformin (oral) and 1.5 nmol/kg body weight GLP-1 sc stat dose D3: 1 g metformin (oral) and 1 ml normal saline sc stat dose




You can take part if:



You may not be able to take part if:


Type 2 diabetes on two or more hypoglycaemic agents or requiring insulin.


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • 11 Village Green
    Northern Ireland
    BT39 0UD

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Dr Joy Cuthbertson
+44 (0)77614 01203
joycuthbertson@msn.com



The study is sponsored by Royal Victoria Hospital (UK) and funded by Northern Ireland Health and Social Services Central Services Agency (UK) - Research and Development Fellowship (ref: EAT/2955/04).




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN37245053
Last updated 25 September 2013

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top